Literature DB >> 21701158

Unusually long survival of a 67-year-old patient with near-tetraploid acute myeloid leukemia m0 without erythroblastic and megakaryocytic dysplasia.

Petr Lemež1, Hana Klamová, Zuzana Zemanová, Iuri Marinov, Ota Fuchs, Jiří Schwarz, Jana Březinová, Dana Provazníková, Arnošt Kostečka, Jana Marková, Kyra Michalová, Jaroslav Jelínek.   

Abstract

Patients with near-tetraploid acute myeloid leukemia (NT-AML) typically have poor survival. We present the case of a 67-year-old Caucasian male with NT-AML M0 who had an unusually long first complete remission of 51 months and an overall survival of 80 months. The only characteristic distinguishing him from other previously described patients with NT-AML was the absence of erythroblastic and/or megakaryocytic dysplasia (EMD) at diagnosis. Molecular-genetic testing for AML fusion transcripts associated with a favorable prognosis (PML/RARα,AML1/ETO, and CBFβ/MYH11) were negative, as were other prognostic markers like MLL-PTD,FLT3-ITD, or mutations of FLT3-D835,NPM1, or CEBPA. Expression studies of ERG,MN1, and EVI1 revealed overexpression of ERG only. The absence of EMD may be a useful prognostic/diagnostic feature of this new rare subtype of NT-AML.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21701158     DOI: 10.1159/000328199

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  2 in total

1.  Clinicopathological analysis of near-tetraploidy/tetraploidy acute myeloid leukaemia.

Authors:  Changlee S Pang; Mark J Pettenati; Timothy S Pardee
Journal:  J Clin Pathol       Date:  2015-01-06       Impact factor: 3.411

Review 2.  A tetraploid minimally differentiated acute myeloblastic leukemia with extensive erythrophagocytosis: a case report and literature review.

Authors:  Li Li; Jianlan Li; Guoxia Li; Yanhong Tan; Xiuhua Chen; Fanggang Ren; Haixiu Guo; Hongwei Wang
Journal:  Int J Hematol       Date:  2012-09-28       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.